Plexxikon Deals Kidney Disease Drug To Roche
This article was originally published in The Pink Sheet Daily
With a three-year financial runway, biotech contends the deal validates its discovery-only business model.
You may also be interested in...
Ruling comes just ahead appeals-court hearing on epoetin follow-on.
Plexxikon’s PLX-4032 could eventually compete against biologics in the colorectal cancer market.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.